
    
      Pfizer suspended enrollment on 21 August 2006 as a precautionary measure in light of the
      mortality imbalance seen in a similar study, and terminated the study on April 6, 2007 due to
      factors affecting the timeline to completion, such as slow enrollment and inclusion of
      sufficient evaluable subjects.
    
  